← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › MUSCLE RELAXANTS › MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS › Other quaternary ammonium compounds
cisatracurium
M03AC11
Forms & Strengths
- Injection: 2 mg/mL (5 mL, 10 mL vials)
- Injection: 10 mg/mL (20 mL vials)
Adult Dosing
- Tracheal intubation: 0.15 to 0.2 mg/kg IV bolus
- Continuous infusion: 1 to 3 mcg/kg/min IV for maintenance during mechanical ventilation
Pediatric Dosing
- Neonates (1 month to <1 month): 0.1 mg/kg IV over 5 to 10 seconds
- Pediatrics (1 month to 12 years): 0.1 to 0.15 mg/kg IV over 5 to 10 seconds; maintenance infusion 1 to 2 mcg/kg/min
Indications
- Adjunct to general anesthesia
- Facilitation of tracheal intubation
- Skeletal muscle relaxation during surgery or mechanical ventilation
Mechanism of Action
- Non-depolarizing skeletal muscle relaxant
- Competitively binds to cholinergic receptors on the motor end-plate, antagonizing acetylcholine and blocking neuromuscular transmission
Contraindications
- Hypersensitivity to cisatracurium or other neuromuscular blocking agents
Adverse Reactions
- Bradycardia
- Hypotension
- Flushing
- Bronchospasm
- Prolonged neuromuscular block
Drug Interactions
- Inadvisable with potent inhalational anesthetics (e.g., isoflurane, enflurane) which enhance neuromuscular blockade
- Synergistic prolongation of block with aminoglycosides, polymyxins, lithium, and magnesium salts
- Anticonvulsants (carbamazepine, phenytoin) may decrease duration of action
Curated Content: Needs Vetting Before Put to Clinical Use